OVID
Ovid Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.89 / 10
Netural
Sentiment is neutral (3.89) but fund flow is strong (7.78) with positive inflows across all size blocks. Analysts are bullish: one Buy rating from Wedbush, though with no track record. Money flow supports the recent rally.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Laura ChicoBuy
Date2026-03-20
InstitutionWedbush
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for OVID?
- OVID holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.89/10 (Netural).
